GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Solstice Oncology acquires porustobart from Harbour Biomed.
2026’s first big oncology buyout is here.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
Darovasertib data are promised for the last week of March.
